Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Carboplatin in Advanced Endometrial Carcinoma: NCT07198074 Clinical Landscape Report 2026
28 September 2026
NCT07198074 clinical landscape for Advanced Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Renal Cell Carcinoma: NCT07195682 Clinical Landscape Report 2026
28 September 2026
NCT07195682 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Loncastuximab tesirine in High grade B-cell lymphoma: NCT07197307 Clinical Landscape Report 2026
28 September 2026
NCT07197307 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CT1194D CAR-T Cells(Hematology Hospital of Chinese Academy of Medical Sciences) in Neoplasms: NCT07200479 Clinical Landscape Report 2026
28 September 2026
NCT07200479 clinical landscape for Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Roginolisib in Uveal Melanoma: NCT07203391 Clinical Landscape Report 2026
28 September 2026
NCT07203391 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Abemaciclib in ER Positive Endometrial Carcinoma: NCT07209449 Clinical Landscape Report 2026
28 September 2026
NCT07209449 clinical landscape for ER Positive Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Anlotinib Dihydrochloride in Locally Advanced Soft Tissue Sarcoma: NCT07205185 Clinical Landscape Report 2026
28 September 2026
NCT07205185 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
i15.NKG2D.zeta-NK cells(Baylor College of Medicine) in Neuroblastoma recurrent: NCT07211737 Clinical Landscape Report 2026
28 September 2026
NCT07211737 clinical landscape for Neuroblastoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
THEO-260 in Ovarian Cancer: NCT07211659 Clinical Landscape Report 2026
28 September 2026
NCT07211659 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Surovatamig in Large B-cell lymphoma: NCT07215585 Clinical Landscape Report 2026
28 September 2026
NCT07215585 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
[68Ga]FAPI-46 in Malignant melanoma stage IV: NCT07215182 Clinical Landscape Report 2026
28 September 2026
NCT07215182 clinical landscape for Malignant melanoma stage IV: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RP-2(Replimune Group) in Metastatic Renal Cell Carcinoma: NCT07218692 Clinical Landscape Report 2026
28 September 2026
NCT07218692 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.